High Pointe Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

High Pointe Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,640	Closed	-$1.74M	–	89
2019 Q4	$1.74M	Buy	4,640 +210	+5%	+$70.7K	2.07%	13
2019 Q3	$1.23M	Buy	4,430 +120	+3%	+$35.5K	1.68%	20
2019 Q2	$1.35M	Hold	4,310	–	–	1.89%	18
2019 Q1	$1.77M	Sell	4,310 -50	-1%	-$20.6K	2.42%	5
2018 Q4	$1.63M	Buy	4,360 +1,220	+39%	+$447K	2.68%	7
2018 Q3	$1.27M	Buy	3,140 +640	+26%	+$244K	1.71%	25
2018 Q2	$862K	Buy	+2,500	New	+$782K	1.23%	35

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

High Pointe Capital Management's REGN Position: Q1 2020 in Review

High Pointe Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2020, closing a stake of 4,640 shares — an estimated $1.74M sold.

High Pointe Capital Management first reported a position in REGN in Q2 2018 and held it in 7 quarters. The position peaked at $1.77M in Q1 2019. 816 funds tracked by Wall St. Rank hold REGN as of Q1 2020.

High Pointe Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
High Pointe Capital Management sold 4,640 Regeneron Pharmaceuticals shares in Q1 2020, an estimated $1.74M.
High Pointe Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 7 quarters.
High Pointe Capital Management's Regeneron Pharmaceuticals position peaked at $1.77M in Q1 2019.
816 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2020.

Based on High Pointe Capital Management's 13F filing for Q1 2020, filed 12 May 2020.